MX365781B - Composicion farmaceutica que comprende derivados de glutarimida y uso de los mismos en el tratamiento de enfermedades eosinofilicas. - Google Patents
Composicion farmaceutica que comprende derivados de glutarimida y uso de los mismos en el tratamiento de enfermedades eosinofilicas.Info
- Publication number
- MX365781B MX365781B MX2016006330A MX2016006330A MX365781B MX 365781 B MX365781 B MX 365781B MX 2016006330 A MX2016006330 A MX 2016006330A MX 2016006330 A MX2016006330 A MX 2016006330A MX 365781 B MX365781 B MX 365781B
- Authority
- MX
- Mexico
- Prior art keywords
- eosinophilic
- application
- glutarimide derivatives
- pharmaceutical composition
- composition containing
- Prior art date
Links
- KNCYXPMJDCCGSJ-UHFFFAOYSA-N piperidine-2,6-dione Chemical class O=C1CCCC(=O)N1 KNCYXPMJDCCGSJ-UHFFFAOYSA-N 0.000 title abstract 3
- 208000027004 Eosinophilic disease Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000002327 eosinophilic effect Effects 0.000 abstract 2
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 abstract 1
- 206010002199 Anaphylactic shock Diseases 0.000 abstract 1
- 208000028185 Angioedema Diseases 0.000 abstract 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 abstract 1
- 206010010744 Conjunctivitis allergic Diseases 0.000 abstract 1
- 206010012438 Dermatitis atopic Diseases 0.000 abstract 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 abstract 1
- 206010064212 Eosinophilic oesophagitis Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010039085 Rhinitis allergic Diseases 0.000 abstract 1
- 206010047115 Vasculitis Diseases 0.000 abstract 1
- 208000002205 allergic conjunctivitis Diseases 0.000 abstract 1
- 230000000172 allergic effect Effects 0.000 abstract 1
- 201000010105 allergic rhinitis Diseases 0.000 abstract 1
- 208000003455 anaphylaxis Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 208000024998 atopic conjunctivitis Diseases 0.000 abstract 1
- 201000008937 atopic dermatitis Diseases 0.000 abstract 1
- 208000010668 atopic eczema Diseases 0.000 abstract 1
- 206010057271 eosinophilic colitis Diseases 0.000 abstract 1
- 201000000708 eosinophilic esophagitis Diseases 0.000 abstract 1
- 201000001564 eosinophilic gastroenteritis Diseases 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000009890 sinusitis Diseases 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
- C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Otolaryngology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RU2013150861/15A RU2552929C1 (ru) | 2013-11-14 | 2013-11-14 | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний |
| PCT/RU2014/000855 WO2015072893A1 (ru) | 2013-11-14 | 2014-11-12 | Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016006330A MX2016006330A (es) | 2016-09-06 |
| MX365781B true MX365781B (es) | 2019-06-13 |
Family
ID=53057723
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016006330A MX365781B (es) | 2013-11-14 | 2014-11-12 | Composicion farmaceutica que comprende derivados de glutarimida y uso de los mismos en el tratamiento de enfermedades eosinofilicas. |
| MX2019006881A MX386887B (es) | 2013-11-14 | 2014-11-12 | Composicion farmaceutica que comprende derivados de glutarimida y uso de los mismos en el tratamiento de enfermedades eosinofilicas |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019006881A MX386887B (es) | 2013-11-14 | 2014-11-12 | Composicion farmaceutica que comprende derivados de glutarimida y uso de los mismos en el tratamiento de enfermedades eosinofilicas |
Country Status (23)
| Country | Link |
|---|---|
| US (2) | US9949962B2 (enExample) |
| EP (2) | EP3466425B1 (enExample) |
| JP (4) | JP2016540749A (enExample) |
| KR (2) | KR102312294B1 (enExample) |
| CN (2) | CN110200968A (enExample) |
| AU (2) | AU2014349246C1 (enExample) |
| BR (1) | BR112016010515B1 (enExample) |
| CA (1) | CA2930231C (enExample) |
| CY (1) | CY1122500T1 (enExample) |
| DK (1) | DK3069720T3 (enExample) |
| EA (4) | EA032955B3 (enExample) |
| ES (2) | ES2759530T3 (enExample) |
| HU (1) | HUE046671T2 (enExample) |
| IL (2) | IL245429B (enExample) |
| LT (1) | LT3069720T (enExample) |
| MX (2) | MX365781B (enExample) |
| PL (2) | PL3069720T3 (enExample) |
| PT (1) | PT3069720T (enExample) |
| RU (1) | RU2552929C1 (enExample) |
| SG (1) | SG10201900504XA (enExample) |
| SI (1) | SI3069720T1 (enExample) |
| UA (1) | UA118687C2 (enExample) |
| WO (1) | WO2015072893A1 (enExample) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7608693B2 (en) | 2006-10-02 | 2009-10-27 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human IL-4 receptor |
| LT2892927T (lt) | 2012-09-07 | 2018-09-10 | Regeneron Pharmaceuticals, Inc. | Atopinio dermatito gydymo būdai, skiriant il-4r antagonistą |
| UA121299C2 (uk) * | 2013-04-12 | 2020-05-12 | Общєство С Огранічєнной Отвєтствєнностью "Фармінтерпрайсез" | Похідні глутарімідів, їх застосування, фармацевтична композиція на їх основі, способи їх одержання |
| TWI634900B (zh) | 2013-07-11 | 2018-09-11 | 再生元醫藥公司 | 藉由投與ｉｌ－４ｒ抑制劑治療嗜酸性食道炎的方法 |
| EP4353254A3 (en) | 2014-02-28 | 2024-07-03 | Regeneron Pharmaceuticals, Inc. | Methods for treating skin infection by administering an il-4r antagonist |
| MX2019002344A (es) | 2016-09-01 | 2019-09-06 | Regeneron Pharma | Metodos de prevenir o tratar la alergia administrando un antagonista de il-4r. |
| CN106539792B (zh) * | 2016-11-07 | 2017-08-25 | 王晓旭 | 一种治疗高血脂症的药物 |
| MD4802C1 (ro) * | 2017-09-07 | 2022-11-30 | Obschestvo S Ogranichennoi Otvetstvennostiyu "Pharmenterprises" | Utilizarea derivatului de glutaramidă pentru tratarea afecţiunilor, asociate cu activitatea aberantă a citokinelor |
| RU2712281C1 (ru) * | 2018-11-23 | 2020-01-28 | Общество С Ограниченной Ответственностью "Хемиммьюн Терапьютикс" | Применение производного глутаримида для преодоления резистентности к стероидам и терапии заболеваний, ассоциированных с аберрантным сигналингом интерферона гамма |
| KR20210143246A (ko) | 2019-03-21 | 2021-11-26 | 리제너론 파아마슈티컬스, 인크. | 알레르기 치료용 il-4/il-13 경로 억제제 및 형질 세포 절제의 병용 |
| EP4010373A1 (en) | 2019-08-05 | 2022-06-15 | Regeneron Pharmaceuticals, Inc. | Methods for treating atopic dermatitis by administering an il-4r antagonist |
| CN114173819A (zh) | 2019-08-05 | 2022-03-11 | 瑞泽恩制药公司 | 通过施用il-4r拮抗剂治疗过敏和增强过敏原特异性免疫疗法的方法 |
| AU2021253849A1 (en) * | 2020-04-07 | 2022-09-22 | Hofseth Biocare Asa | Respiratory treatments using salmonid oil compositions |
| BR112022026356A2 (pt) * | 2020-06-26 | 2023-01-17 | Valenta Intellekt Ltd | Uso de um derivado de glutarimida para tratar doenças associadas à atividade aberrante da interleucina-6 |
| WO2023113650A1 (ru) * | 2021-12-15 | 2023-06-22 | Владимир Евгеньевич НЕБОЛЬСИН | Фармацевтическая композиция 1-[2-(1-метилимидазол-4-ил)-этил]пергидроазин-2,6-дион для терапии заболеваний верхних дыхательных путей |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH02196767A (ja) | 1988-10-11 | 1990-08-03 | Kyowa Hakko Kogyo Co Ltd | ヒドロキサム酸誘導体 |
| EP0564520A1 (en) | 1990-12-24 | 1993-10-13 | Merrell Dow Pharmaceuticals Inc. | Use of certain glutarimide derivatives in the treatment of depression and mania |
| WO1994024133A1 (en) | 1993-04-09 | 1994-10-27 | Cell Therapeutics, Inc. | Ring-substituted cell signaling inhibitors |
| AUPO005496A0 (en) | 1996-05-24 | 1996-06-13 | Bresagen Limited | An interleukin-5 antagonist |
| RU2141483C1 (ru) | 1997-07-04 | 1999-11-20 | Небольсин Владимир Евгеньевич | Производные пептидов или их фармацевтически приемлемые соли, способ их получения, применение и фармацевтическая композиция |
| NZ532516A (en) | 2001-11-07 | 2008-05-30 | Cytos Biotechnology Ag | Antigen arrays presenting IL-5, IL-13 or eotaxin for treatment of allergic eosinophilic diseases |
| EP1741709A1 (en) * | 2005-06-28 | 2007-01-10 | Sanofi-Aventis Deutschland GmbH | Heteroaryl-substituted amides comprising a saturated linker group, and their use as pharmaceuticals |
| WO2007007054A1 (en) | 2005-07-08 | 2007-01-18 | Cancer Research Technology Limited | Phthalamides, succinimides and related compounds and their use as pharmaceuticals |
| MX2009012341A (es) | 2007-05-14 | 2010-02-17 | Medimmune Llc | Metodos para reducir niveles de eosinofilos. |
| RU2378284C2 (ru) * | 2008-02-13 | 2010-01-10 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Способы получения n-ацильных производных аминокислот (варианты) |
| RU2406727C2 (ru) * | 2008-02-13 | 2010-12-20 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Фармацевтическая композиция, содержащая n-ацильные производные аминокислот, и их применение в качестве противоаллергических, антианафилактических и противовоспалительных средств |
| UA121299C2 (uk) * | 2013-04-12 | 2020-05-12 | Общєство С Огранічєнной Отвєтствєнностью "Фармінтерпрайсез" | Похідні глутарімідів, їх застосування, фармацевтична композиція на їх основі, способи їх одержання |
-
2013
- 2013-11-14 RU RU2013150861/15A patent/RU2552929C1/ru active
-
2014
- 2014-11-12 ES ES14861410T patent/ES2759530T3/es active Active
- 2014-11-12 PL PL14861410T patent/PL3069720T3/pl unknown
- 2014-11-12 AU AU2014349246A patent/AU2014349246C1/en not_active Ceased
- 2014-11-12 CN CN201910373584.XA patent/CN110200968A/zh active Pending
- 2014-11-12 EA EA201891262A patent/EA032955B3/ru not_active IP Right Cessation
- 2014-11-12 KR KR1020167013675A patent/KR102312294B1/ko not_active Expired - Fee Related
- 2014-11-12 KR KR1020207013125A patent/KR102312013B1/ko not_active Expired - Fee Related
- 2014-11-12 EA EA201690798A patent/EA030961B1/ru not_active IP Right Cessation
- 2014-11-12 SG SG10201900504XA patent/SG10201900504XA/en unknown
- 2014-11-12 WO PCT/RU2014/000855 patent/WO2015072893A1/ru not_active Ceased
- 2014-11-12 CA CA2930231A patent/CA2930231C/en active Active
- 2014-11-12 EA EA201891261A patent/EA032940B1/ru not_active IP Right Cessation
- 2014-11-12 PT PT148614100T patent/PT3069720T/pt unknown
- 2014-11-12 HU HUE14861410A patent/HUE046671T2/hu unknown
- 2014-11-12 BR BR112016010515-0A patent/BR112016010515B1/pt not_active IP Right Cessation
- 2014-11-12 CN CN201480062492.5A patent/CN105722511B/zh not_active Expired - Fee Related
- 2014-11-12 US US15/036,603 patent/US9949962B2/en active Active
- 2014-11-12 EP EP18206980.7A patent/EP3466425B1/en active Active
- 2014-11-12 SI SI201431407T patent/SI3069720T1/sl unknown
- 2014-11-12 PL PL18206980T patent/PL3466425T3/pl unknown
- 2014-11-12 EA EA201990529A patent/EA037447B1/ru unknown
- 2014-11-12 LT LTEP14861410.0T patent/LT3069720T/lt unknown
- 2014-11-12 DK DK14861410T patent/DK3069720T3/da active
- 2014-11-12 MX MX2016006330A patent/MX365781B/es active IP Right Grant
- 2014-11-12 EP EP14861410.0A patent/EP3069720B1/en active Active
- 2014-11-12 ES ES18206980T patent/ES2836887T3/es active Active
- 2014-11-12 MX MX2019006881A patent/MX386887B/es unknown
- 2014-11-12 JP JP2016530898A patent/JP2016540749A/ja not_active Ceased
- 2014-12-11 UA UAA201606370A patent/UA118687C2/uk unknown
-
2016
- 2016-05-01 IL IL245429A patent/IL245429B/en active IP Right Grant
-
2017
- 2017-12-18 US US15/844,703 patent/US10220029B2/en active Active
-
2018
- 2018-10-30 JP JP2018203599A patent/JP6589251B2/ja active Active
- 2018-11-15 AU AU2018264084A patent/AU2018264084C1/en not_active Ceased
-
2019
- 2019-08-21 JP JP2019151258A patent/JP2020002152A/ja not_active Ceased
- 2019-08-21 JP JP2019151253A patent/JP6758677B2/ja not_active Expired - Fee Related
- 2019-11-19 CY CY20191101215T patent/CY1122500T1/el unknown
- 2019-12-11 IL IL271352A patent/IL271352B/en active IP Right Grant
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX365781B (es) | Composicion farmaceutica que comprende derivados de glutarimida y uso de los mismos en el tratamiento de enfermedades eosinofilicas. | |
| HK1231471A1 (zh) | 6-杂芳氧基-和6芳氧基-喹啉-2-甲酰胺及其用途 | |
| GEP20207105B (en) | 1,1,1-trifluoro-3-hydroxypropan-2-yl carbamate derivatives and 1,1,1-trifluoro-4-hydroxybutan-2yl carbamate derivatives as magl inhibitors | |
| WO2014028600A3 (en) | 3-AMINOCYCLOALKYL COMPOUNDS AS RORgammaT INHIBITORS AND USES THEREOF | |
| WO2013163190A8 (en) | Dna-pk inhibitors | |
| MX368263B (es) | Compuestos novedosos y composiciones farmaceuticas de los mismos para el tratamiento de fibrosis quistica. | |
| MY178621A (en) | Deuterated cftr potentiators | |
| MX344335B (es) | Derivados de benzonitrilo como inhibidores de cinasa. | |
| MD4666B1 (ro) | Inhibitori ai Syk | |
| UA109868C2 (ru) | Соединения n-алкилтриазола как антагонисты лизофосфатидной кислоты (lpar) | |
| PH12014502363A1 (en) | N-aryltriazole compounds as lpar antagonists | |
| WO2014179564A8 (en) | Thiazolopyrrolidine inhibitors of ror-gamma | |
| MX363457B (es) | Compuestos de sulfonamida heterociclica sustituida utiles como moduladores del canal del receptor de potencial transitorio a1 (trpa1). | |
| WO2011107608A8 (en) | Heterocyclic amides as rock inhibitors | |
| PH12017502201A1 (en) | Substituted pyridines and method of use | |
| NZ719185A (en) | Crystalline forms of therapeutic compounds and uses thereof | |
| HK1210174A1 (en) | Serine/threonine kinase inhibitors for the treatment of hyperproliferative|diseases | |
| WO2014155300A3 (en) | Substitued pyrimidine amine derivatives as tak-1 inhibitors | |
| PH12014501967B1 (en) | Benzodioxanes in combination with other actives for inhibiting leukotriene production | |
| WO2014016849A3 (en) | Novel triazine compounds | |
| CA2929436C (en) | Compounds, pharmaceutical composition and methods for use in treating inflammatory diseases | |
| WO2012119006A3 (en) | Derivatives of pyrazole-substituted amino-heteroaryl compounds | |
| MX2018004879A (es) | Nuevos derivados de piridona y su uso como inhibidores de quinasas. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |